December 13, 2024 US FDA lifts partial clinical hold on BioNTech cancer drug study BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration ...

We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like ...

When the smoke cleared, BioNTech's shares closed the day more than 6% lower. The Food and Drug Administration (FDA), a ...

As BioNTech progresses with its goal to grow into a “fully integrated immunotherapy powerhouse,” the German biotech is e | ...

2025 SG&A Expense Guidance: EUR650 million to EUR750 million. BioNTech SE (NASDAQ:BNTX) made significant progress in 2024 towards its vision of becoming an immunotherapy powerhouse, particularly ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on BioNTech SE (BNTX – Research Report). The company’s shares closed yesterday at $104.68.

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's first ...